Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vivesto AB ( (SE:VIVE) ) just unveiled an announcement.
Vivesto AB has initiated a dose-finding study for its drug candidate Paccal Vet in cats with solid tumors, marking a significant advancement in veterinary oncology as there are currently no approved cancer drugs for cats. The study aims to determine the maximum tolerated dose and explore the drug’s anti-tumor efficacy, potentially positioning Paccal Vet as a breakthrough treatment option in the veterinary market.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on providing new treatment options for hard-to-treat cancers with significant medical needs and market potential. Their project portfolio includes Cantrixil for blood cancer and the veterinary oncology program Paccal Vet, which is being evaluated in clinical trials for dogs and cats.
Average Trading Volume: 387,958
Technical Sentiment Signal: Sell
Current Market Cap: SEK129.7M
For an in-depth examination of VIVE stock, go to TipRanks’ Overview page.